Chinese biotech Hutchmed has completed its rolling marketing application in the US for oral VEGF receptor inhibitor fruquintinib, which was licensed by Takeda for a hefty
For the newest pharmaphorum podcast, editor-in-chief Jonah Comstock welcomes Dr Kristina Allikmets, SVP and head of R&D at Takeda’s plasma-derived therapies business unit.
It’s a case of so far, so good for Takeda as it reports solid data for the TYK2 inhibitor it licensed from Nimbus Therapeutics for a massive $4 billion upfront in December
CSL has fleshed out the data from its phase 3 trial of garadacimab, a once-monthly therapy for hereditary angioedema (HAE), preparing regulatory filings and an attempt to
Chinese biotech Hutchmed's push to sign partnerships for its drug products outside its home market has resulted in a $1.13 billion deal with Japan's Takeda, including a hefty upfront fee of
Boehringer Ingelheim and Takeda are the only two pharmaceutical groups to be named among the 15 Global Top Employers for 2023, an award dedicated to companies that enrich the workplace envi
Bavarian Nordic is preparing to file for regulatory approval of a vaccine against chikungunya virus after its CHIKV VLP candidate showed protective efficacy in a second ph
To improve trial recruitment, engagement, and retention, and to increase the likelihood that trials reflect what matters most to patients, regulatory authorities increasingly point to metho